학술논문
MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study
Document Type
Abstract
Author
Ayala, Rosa; Lopez, Nieves; Abulafia, Adi Shacham; Alwan, Maan; Yannakou, Costas K.; Raman, Indu; Ribrag, Vincent; Fong, Chun Yew; Volchek, Yulia; Bonifacio, Massimiliano; Tucci, Alessandra; Kiladjian, Jean-Jacques; Rivas, Jésus Marïa Hernandez; Xicoy, Blanca; Al-Ali, Haifa; Ianotto, Jean-Christope; Lee-Hoeflich, Si Tuen; Das, Sharmilla; Wu, Bin; Ravindran, Palanikumar; Zhao, Qian; Wang, Guan; Esposito, Oriana; Liu, Yu; Nikolova, Zariana; Tehlirian, Christopher; Coker, Shodeinde; Lavie, David
Source
In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S391-S392
Subject
Language
ISSN
2152-2650